ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / BLLN
CON (68) RDNT (57) CDNA (71) GRAL (54) ⌘ Pro Terminal β†’

BillionToOne Inc. (BLLN) β€” RQD Stock Rating Cockpit

$110.41 -2.57% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $110.16

BillionToOne Inc. (BLLN) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (68.3% gross margin, 3% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- β€’ BUY Cap $5.35B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BLLN Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is BLLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, BillionToOne Inc. (NASDAQ: BLLN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $110.41 (-2.57% 1D, market cap $5.35B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, BLLN ranks #75 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does BLLN compare to CON and RDNT in the Health Care sector?
β–Ό

Within the Health Care sector (Medical Specialities), BLLN carries a Roarable B- (70/100 RQD), trailing P/E of N/A, gross margin of 68.3%, and ROIC of 2.9%. By comparison, CON (Concentra Group Holdings Parent Inc.) holds a C+ grade (68/100 RQD, P/E 31.6x, ROIC 19.7%, cap $5.15B) and RDNT (RadNet Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC 3.5%, cap $5.78B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BLLN?
β–Ό

Per BLLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002070849), BillionToOne Inc. generated $305.1M in revenue (+100.0% YoY), $7.5M in net income, and $15.7M in free cash flow against $632.7M in total assets and $57.2M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $110.17 (-0.22%)🧬 Disciplined Float (+1.08% YoY Shares)βš™οΈ Cash Engine: 14/20 (B-) β€’ 5.2% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 70/100 (B-) historically ranked in the Top 15% of excess returns over the next 90 days (+6.6% avg 90D alpha vs SPY β€’ 68.1% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERBUY β€’ B-
025507510070
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C Β· Rk A-
Cash (14)Whales (15)SEC (18)Macro (15)CEO (8)
Each axis scored 0–20
12M PRICE TARGET CONE+5.4% Base Target
$158 Bull$116 Base$91 Bear
πŸ“¬ FREE BLLN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for BLLN)Realized 20D OHLCV Swing Band: Β±10.3%
Deterministic 5-Pillar Attribution (70/100 Composite)
πŸ” WHY BLLN SCORES 70/100 (B-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (26% of score)

Altman Z-Score 22.24 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 9/9

β–² #2 Bullish Driver: Whale & Options Positioning+15/20 pts (21% of score)

20D Institutional Volume Accumulation (Β±10.3% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)

Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
62
Grade C+$97.88+6.9% Next Q
Q2 (-2Q)
65
Grade C+$104.67+8.9% Next Q
Q3 (-1Q)
67
Grade B-$114.00-3.1% Next Q
Current
70
Grade B-$110.41+6.6% Hist 90D Ξ±
Trajectory: C+ (62) β†’ B- (70)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the BLLN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 70/100 (B-) score, BLLN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+1.08% YoY Shares) β€” any gross margin slip below 65.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($104.83) or 200D SMA ($96.81) invalidates the momentum regime and cuts Target Base ($116.37) toward Bear Floor ($90.54).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BLLNβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œBLLN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 70%NO 30%Trade / Inspect Odds β†’
RSI-14 MOMENTUMBULLISH MOMENTUM
58.430 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
22.24>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE55% OF RANGE
L: $62$110.41H: $150
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (68.3% gross margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: B-RQD 14 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 23 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: A-RQD 33 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bullish on BLLN

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (70)

2.9% ROIC with 68.3% gross margin and 0.29% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 22.24 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (63)

23/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like BLLN
  • βœ“Big institutional funds and options desks are actively positioning on the bullish side.
  • βœ“Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (BLLN Tape Review)

  • βœ“Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • βœ“Forensic Red-Light accounting & dilution traps to review on your watchlist
  • βœ“Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
BLLN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +53.09%⚑ TESTING RESISTANCE
2026-11-03O $114.8H $114.8L $110.4C $110.4VOL 468.5K
RES: $116.6SUP: $91.51SMA50: $104.8SMA200: $96.81
$156.0$132.9$109.8$86.74$63.64RES $116.6SUP $91.51$110.42026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BLLN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ BLLN Butterfly Map β†’ + Track BLLN β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
48.0%/yr Implied 5Y Growth

vs. +100.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BLLN today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for BLLN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BLLN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BLLN)

Health Care Rank #75 of 1015 βš”οΈ CON vs BLLN Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (BLLN vs. CON, RDNT, CDNA, GRAL)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, BillionToOne Inc. (BLLN) ranks #75 by composite RQD confidence (70/100, grade B-) and #153 by equity capitalization ($5.35B). Within this direct 5-issuer industry benchmark cohort, CON leads on earnings valuation at 31.6x trailing P/E, while CON leads on capital efficiency and profitability with 19.7% ROIC and β€” gross margin. CDNA currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with BLLN at 70/100 (B-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BLLN ACTIVE
BillionToOne Inc.
B- 70/100 β€” 68.3% 2.9% -2.57% $5.35B Benchmark Subject
CON
Concentra Group Holdings Parent Inc.
C+ 68/100 31.6x β€” 19.7% -0.12% $5.15B /con-vs-blln β†’
RDNT
RadNet Inc.
D+ 57/100 β€” β€” 3.5% -0.53% $5.78B /rdnt-vs-blln β†’
CDNA
CareDx Inc.
B- 71/100 β€” β€” -8.2% -1.75% $4.59B /cdna-vs-blln β†’
GRAL
GRAIL Inc.
D+ 54/100 β€” β€” -18.0% -6.74% $6.41B /gral-vs-blln β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0002070849 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BillionToOne Inc. (BLLN) reported GAAP revenue of $305.1M (+100.0% vs. FY2024 revenue of $152.6M , and +325.4% cumulative change since FY2023) , GAAP net income of $7.5M, operating cash flow of $24.6M, and free cash flow of $15.7M (+133.6% YoY). On the balance sheet, BLLN closed FY2025 with $632.7M in total assets against $57.2M in total debt (Altman Z-Score: 22.24, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $305.1M $7.5M $24.6M $15.7M $632.7M $57.2M
FY2024 (FY) 2024-12-31 $152.6M -$41.6M -$41.4M -$46.8M $302.1M $51.5M
FY2023 (FY) 2023-12-31 $71.7M -$82.7M -$53.7M -$56.9M $2.98B $697.4M

3. BLLN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BLLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, BillionToOne Inc. (NASDAQ: BLLN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $110.41 (-2.57% 1D, market cap $5.35B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, BLLN ranks #75 in composite RQD confidence.

How does BLLN compare to CON and RDNT in the Health Care sector?

Within the Health Care sector (Medical Specialities), BLLN carries a Roarable B- (70/100 RQD), trailing P/E of N/A, gross margin of 68.3%, and ROIC of 2.9%. By comparison, CON (Concentra Group Holdings Parent Inc.) holds a C+ grade (68/100 RQD, P/E 31.6x, ROIC 19.7%, cap $5.15B) and RDNT (RadNet Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC 3.5%, cap $5.78B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BLLN?

Per BLLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002070849), BillionToOne Inc. generated $305.1M in revenue (+100.0% YoY), $7.5M in net income, and $15.7M in free cash flow against $632.7M in total assets and $57.2M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BLLN trading relative to its 50-day, 200-day, and 52-week technical levels?

BLLN last traded at $110.41 (-2.57% on volume of 636,121 shares), positioning the stock +5.32% above its 50-day simple moving average ($104.83) and +14.05% above its 200-day simple moving average ($96.81). Across its 52-week range of $61.96 to $150.44, BLLN sits at the 54.8% percentile with a 14-day RSI of 58.4 (BULLISH MOMENTUM) and an implied next-earnings move of Β±10.3% ($99.04 to $121.78).

Direct Sub-Reports: BLLN RQD Cockpit BLLN 12M Forecast BLLN Earnings & Move BLLN Dividends & DRIP BLLN Insiders & 13F BLLN Whale Options BLLN Profit Sankey BLLN News & Why
ROARABLE RATING BRIEF β€’ RQD 70/100 (B-) βœ“ SEC XBRL & RQD VERIFIED

BLLN β€” BillionToOne Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

BillionToOne Inc. (BLLN) earns a live Roarable RQD composite score of 70/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $110.41 (-2.57% 1D, market capitalization $5.35B).

  • Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 2.9%, gross margin of 68.3%, operating margin of 5.3%, and free cash flow yield of 0.29%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (15/20) + Forensic Balance Sheet (18/20): Incorporates a 1.02x equity beta, Altman Z-Score of 22.24, Piotroski F-Score of 9/9, and Debt/Equity of 0.12x.

2. Business Model, Unit Margins & SEC Financial Trajectory

BillionToOne Inc. Is a NASDAQ-listed issuer classified under the Health Care sector and the Medical Specialities industry. The reported margins are a gross margin of 68.3%, an operating margin of 5.3%, and a net margin of 2.4%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), BillionToOne Inc. (BLLN) reported $305.1M in annual revenue (up from $152.6M in FY2024, +100.0% YoY) and $7.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($71.7M revenue, -$82.7M net income) through FY2025, BLLN scaled operating cash flow to $24.6M and free cash flow to $15.7M, backed by $632.7M in total assets against $57.2M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (B- β€’ RQD 70/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $61.96 – $150.44 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation and 95.0x EV/EBITDA against 5.3% operating margins and a 1.02x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Watch items from the news wire that relate to second-order exposure are limited to the insider selling reports already noted.

  • Key Question #1: Can BLLN sustain or expand its 5.3% operating margin and 2.9% ROIC against Medical Specialities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $305.1M and free cash flow of $15.7M, how will capital allocation balance growth reinvestment against $57.2M in total debt?
  • Key Question #3: How sensitive is BLLN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.02x)?

BLLN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BillionToOne Inc. (BLLN) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to BLLN Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BLLN Bull vs. Bear Conversation Board β€” What's Your Call at $110.41?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BLLN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BLLN:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER β€’ Swing & Catalyst Trader πŸ‚ BULLISH 🎯 Target: $131.45 (+16.0%)
πŸ“Œ Pinned Debate

Revenue rose from $71.7M in FY 2023 to $305.1M in FY 2025 while the Roarable forensic pillar scored 18/20 with cash of $496.0M against

Picked up a starter position in BLLN in my $100K Virtual Cash book at $113.32. Revenue rose from $71.7M in FY 2023 to $305.1M in FY 2025 while the Roarable forensic pillar scored 18/20 with cash of $496.0M against debt of $57.2M.. Trading inside a $61.96–$150.44 52-week range with 0.29% FCF yield gives solid downside support if Medical Specialities multiples expand this quarter.

RetailWhale_TX πŸ‚ BULL

@SkepticalCFA Shorting a 15/20 institutional whale-flow stock at $113.32 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER β€’ Fundamental Contrarian 🐻 BEARISH 🎯 Target: $94.06 (-17.0%)
Spot @ $113.32

The stock trades at an EV/EBITDA of 95 with an FCF yield of 0.29% and ROIC of 2.9%, while insider sales are flagged in recent news.

Fading this rally in BLLN at $113.32. The stock trades at an EV/EBITDA of 95 with an FCF yield of 0.29% and ROIC of 2.9%, while insider sales are flagged in recent news.. With a beta of 1.02 and the stock sitting at $113.32 (52-wk range $61.96–$150.44), the easy multiple expansion is already priced in.

LIVE TAPE